Equity Research

Capital ideas from the industry’s brightest minds.

Our award-winning equity research analysts deliver superior investment ideas and value-added perspective for nearly 650 companies, across seven growth-oriented sectors: consumer; energy and sustainability; financial services and technology; global industrial infrastructure; global services; healthcare; and technology, media, and communications. William Blair’s research universe is well-diversified geographically and ranges in market capitalization with an emphasis on small- and mid-cap stocks.
Abstract chart (blue overlay)

companies under
research coverage

Chairs at a conference room table (green overlay)

of coverage dedicated to small- and mid-cap growth companies

Buildings (purple overlay)

analysts and research

As of December 31, 2023

William Blair analysts seek to cover only companies that have above-average growth prospects and above-average quality. They use multiple factors to identify high-quality companies with attractive growth prospects, including the company’s product line, level of service, and management experience.

Our clients include:

  • Mutual Funds
  • Investment Advisory Firms
  • Banks
  • Pension Funds
  • Insurance Companies
  • Money Managers Across North America, Europe, and Asia

Through exhaustive fundamental research and unique insight derived from independent thinking, our award-winning analysts work tirelessly to identify companies that can deliver superior investment returns for our clients.

Recent News

Alto Neuroscience, Inc.: Initiation of Research Coverage

William Blair initiated research coverage of Alto Neuroscience, Inc. (ANRO $13.72), a company focused on developing novel therapies for high-unmet-need indications in psychiatry supported by AI-enabled precision approaches to identify response biomarkers.

Read more

Keros Therapeutics, Inc.: Initiation of Research Coverage

William Blair initiated research coverage of Keros Therapeutics, Inc. (KROS $59.49), a company focused on the development of novel therapies targeting the TGF-β superfamily of cytokines, which play essential roles in the proliferation and differentiation of numerous cell types.

Read more

AAR Corp.: Initiation of Research Coverage

William Blair initiated research coverage of AAR Corp. (AIR $57.14), a provider of supply chain and maintenance, repair, and overhaul (MRO) services for commercial aviation and government customers.

Read more

William Blair Thinking Podcast

Navigating the current market environment demands the right informational resource. That is why we launched the William Blair Thinking Podcast, which aims to provide in-depth expertise on today's financial and economic landscape.

What's different about this platform?
It's our most timely and best ideas—the ethos, if you will, of our firm's intellectual capital. All in 20 minutes.

Our latest podcasts

Featured Insights

The Economics Behind the GLP-1 Phenomenon

Equity research analyst Ryan Daniels examines the growing impact of GLP-1 drugs on healthcare spending and care delivery, along with the needs for health providers, employers, and consumers to effectively manage the emerging wave of GLP-1 drugs.

Read more

Scratching Below the Surface of the Economic Data

While some may be declaring victory in the recession/no-recession debate, there is plenty of evidence to suggest that growth may not be nearly as strong as it seems to be on the surface. Richard de Chazal examines the six data points he believes investors should be cognizant of.

Read more

Corporate Access

Our non-deal roadshows, conferences, and investor field trips facilitate the exchange of ideas and build relationships between senior corporate management and key decision makers with leading institutional investors.

Learn more
People in a conference room

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures